# Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

> **NCT05027633** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Squamous Cell Carcinoma
- the Nasal Cavity
- Paranasal Sinuses

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05027633
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-02
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027633, "Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05027633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*